These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28845514)

  • 1. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
    Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
    Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
    Asai A; Miyata Y; Matsuo T; Shida Y; Hakariya T; Ohba K; Sakai H
    Prostate; 2017 Feb; 77(3):255-262. PubMed ID: 27527525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
    Pu XY; Wang XH; Wu YL; Wang HP
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.
    Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
    Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
    Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
    Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
    Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer.
    Hu JC; Hung SC; Ou YC
    Anticancer Res; 2017 Jun; 37(6):3143-3150. PubMed ID: 28551656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy.
    Wang F; Zhang G; Tang Y; Wang Y; Li J; Xing N
    Front Endocrinol (Lausanne); 2023; 14():1270594. PubMed ID: 37941905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy.
    Naiki T; Kawai N; Okamura T; Nagata D; Kojima Y; Akita H; Yasui T; Tozawa K; Kohri K
    BMC Urol; 2012 Dec; 12():36. PubMed ID: 23249358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
    Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
    Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
    Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.
    Fujita N; Koie T; Ohyama C; Tanaka Y; Soma O; Matsumoto T; Yamamoto H; Imai A; Tobisawa Y; Yoneyama T; Hatakeyama S; Hashimoto Y
    Int J Clin Oncol; 2017 Dec; 22(6):1087-1093. PubMed ID: 28681153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
    Joung JY; Kim JE; Kim SH; Seo HK; Chung J; Park WS; Hong EK; Lee KH
    BMC Urol; 2015 Aug; 15():82. PubMed ID: 26269129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Analysis of Perioperative Outcomes on Neoadjuvant Hormone Therapy before Laparoscopic and Robot-Assisted Surgery for Localized High-Risk Prostate Cancer in a Chinese Cohort.
    Sun G; Liang Z; Jiang Y; Ma S; Chen S; Liu R
    Curr Oncol; 2022 Nov; 29(11):8668-8676. PubMed ID: 36421336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching.
    Kim SH; Park EY; Joo J; Joung JY; Seo HK; Chung J; Lee KH
    Biomed Res Int; 2018; 2018():4307207. PubMed ID: 30627554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
    Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
    Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life.
    Namiki S; Saito S; Tochigi T; Kuwahara M; Ioritani N; Yoshimura K; Terai A; Koinuma N; Arai Y
    Int J Urol; 2005 Feb; 12(2):173-81. PubMed ID: 15733112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.